Etude clinique de la thérapie cellulaire dans le covid-19

Today we have treated five patients suffering from COVID-19 complications in Iran under Iranian Registry of Clinical Trials authority program, which is part of the I.R. Coronavirus Treatment Acceleration Program, an emergency program for possible therapies that uses every available method to move new treatments to patients as quickly as possible.
The patients were treated with UC-MSC (CytoStem hUC-XF Clinical grade) therapy at multi medical centers in Tehran, acute care facilities that are currently active sites for Cell Genes Phase II/ III COVID-19 cell therapy program. Prior to cell therapy treatment with CytoStem hUC-XF Clinical grade, the patients were critically ill with respiratory failure due to acute respiratory distress syndrome (ARDS) and were under Bi-level Positive Airway Pressure (BiPAP) in an intensive care unit (ICU) for two weeks.
4 weak follow up represents for 5 patients treated with CytoStem cells:
• The survival rate of the 5 patients treated with CytoStem cells was 100%
• 100% were off from BiPAP
• 100% were discharged alive from the hospital compared to 30% (patients requiring Non-Invasive Ventilatory Support)

Click to download PDF
Retour haut de page

Hi
Here you can see some frequently asked questions or contact us!

What passage are your cells?

Our human mesenchymal stem/stromal cells (hMSCs) are provided at a population doubling level (PDL) of 8-10 post-mononuclear isolation (Bone Marrow; Equivalent Passage 2) or 14-18 post-isolation from the perivascular region of Wharton’s Jelly (Umbilical Cord; Equivalent Passage 3). Due to variabilities of seeding and harvest densities we characterize our MSC “True Age” in terms of their PDL.

How often should I feed your cells?

A: There is no need to feed cells between passages. Our media is engineered to be a batch culture media, where no media exchange or feed is necessary when following our suggested protocols.

Are your vials sold from pooled donors?

No, we do not pool donors at any time during our production. Master Cell Banks (MCBs) are created from each donor source. Working Cell Banks (WCBs) are produced from our MCBs for general product sales.

What characterization do you provide for your hMSCs?

We characterize our hMSCs by following ISCT criteria: cell identity (surface marker expression), functional potency (angiogenic cytokine and IDO secretion), and trilineage differentiation (adipo-, osteo-, and chondrogenesis). This information is provided to allow customers to choose the optimal hMSC tissue type and donor for their specific application or target indication.